← Back to Search

simethicone for Bubble Colonoscopy

N/A
Waitlist Available
Led By David Kastenberg, MD
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
-Elective outpatients undergoing colonoscopy using split dose PEG-ELS with sodium ascorbate and ascorbic acid
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of colonoscopy
Awards & highlights
Approved for 10 Other Conditions
No Placebo-Only Group
All Individual Drugs Already Approved

Summary

The purpose of this study is to determine whether the administration of PEG along with simethicone will reduce the incidence of colonic bubbles that interfere with polyp detection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at time of colonoscopy
This trial's timeline: 3 weeks for screening, Varies for treatment, and at time of colonoscopy for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Efficacy - Entire colon
Secondary study objectives
Adenoma detection
Efficacy - Right colon
Flushing
+2 more

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Active Control
Group I: no simethiconeActive Control1 Intervention
Group II: simethiconeActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
462 Previous Clinical Trials
175,398 Total Patients Enrolled
David Kastenberg, MDPrincipal InvestigatorThomas Jefferson University
3 Previous Clinical Trials
1,135 Total Patients Enrolled
~9 spots leftby Nov 2025